An open-label, multiple dose, randomized, three-period crossover study in healthy volunteers to evaluate the effect of co-administration of amantadine 100 mg bid and oseltamivir 75 mg bid on the pharmacokinetic properties of amantadine and oseltamivir
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2007
At a glance
- Drugs Amantadine (Primary) ; Oseltamivir (Primary)
- Indications Parkinson's disease; Viral infections
- Focus Pharmacokinetics
- Sponsors Novartis
- 29 Nov 2007 Status change from in progress to completed.
- 03 Feb 2007 New trial record.